Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)
The summary for the Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed): This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT.
Federal Grant Title: | Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Environment Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-ES-23-008 |
Type of Funding: | Grant |
CFDA Numbers: | 93.113 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | July 7th, 2023 |
Original Application Deadline: | July 7th, 2023 |
Posted Date: | March 21st, 2023 |
Creation Date: | March 21st, 2023 |
Archive Date: | August 12th, 2023 |
Total Program Funding: | |
Maximum Federal Grant Award: | $295,924 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | March 21st, 2023 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-008.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
- • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
- • NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed...
- • NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advan...
- • Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clini...
- • Outstanding New Environmental Scientist Award (ONES)
- • Environmental Health Sciences Core Center Grants
- • Leiomyomata Uteri: Basic Science and Translational Research
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)